Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)
- Authors:
- Jingyi He
- Zhengrong Huang
- Linzhi Han
- Yan Gong
- Conghua Xie
-
Affiliations: Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China - Published online on: September 24, 2021 https://doi.org/10.3892/ijo.2021.5270
- Article Number: 90
-
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Testa U, Castelli G and Pelosi E: Lung cancers: Molecular characterization, clonal heterogeneity and evolution, and cancer stem cells. Cancers (Basel). 10:2482018. View Article : Google Scholar | |
|
Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, et al: Screening for epidermal growth factor receptor mutations in lung cancer. New Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
da Cunha Santos G, Shepherd FA and Tsao MS: EGFR mutations and lung cancer. Annu Rev Pathol. 6:49–69. 2011. View Article : Google Scholar | |
|
Roskoski R Jr: Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. 139:395–411. 2019. View Article : Google Scholar | |
|
Huang L and Fu L: Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 5:390–401. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kazandjian D, Blumenthal GM, Yuan W, He K, Keegan P and Pazdur R: FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer. Clin Cancer Res. 22:1307–1312. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP, Ding CM, Song X, Ma ZY, Ren XL, et al: First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): A phase 3, open-label, randomized study. Ann Oncol. 28:2443–2450. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, et al: Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial. Lancet Oncol. 17:577–589. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, et al: Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A randomised, open-label, phase 3 trial. Lancet Oncol. 18:1454–1466. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, et al: Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial. Lancet Oncol. 13:528–538. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ellis PM, Shepherd FA, Millward M, Perrone F, Seymour L, Liu G, Sun S, Cho BC, Morabito A, Leighl NB, et al: Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): A double-blind, randomised, phase 3 trial. Lancet Oncol. 15:1379–1388. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Westover D, Zugazagoitia J, Cho BC, Lovly CM and Paz-Ares L: Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 29(Suppl-1): i10–i19. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Passaro A, Guerini-Rocco E, Pochesci A, Vacirca D, Spitaleri G, Catania CM, Rappa A, Barberis M and de Marinis F: Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment. Pharmacol Res. 117:406–415. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, et al: Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. New Engl J Med. 376:629–640. 2017. View Article : Google Scholar | |
|
Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4:1046–1061. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, et al: Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. New Engl J Med. 378:113–125. 2018. View Article : Google Scholar | |
|
Sequist LV, Soria JC and Camidge DR: Update to rociletinib data with the RECIST confirmed response rate. New Engl J Med. 374:2296–2297. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yun J, Hong MH, Kim SY, Park CW, Kim S, Yun MR, Kang HN, Pyo KH, Lee SS, Koh JS, et al: YH25448, an irreversible EGFR-TKI with potent intracranial activity in EGFR mutant non-small cell lung cancer. Clin Cancer Res. 25:2575–2587. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Xu X, Mao L, Xu W, Tang W, Zhang X, Xi B, Xu R, Fang X, Liu J, Fang C, et al: AC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance in animal models and lung cancer patients. Mol Cancer Ther. 15:2586–2597. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Jia Y, Juarez J, Li J, Manuia M, Niederst MJ, Tompkins C, Timple N, Vaillancourt MT, Pferdekamper AC, Lockerman EL, et al: EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor. Cancer Res. 76:1591–1602. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yu HA, Spira A, Horn L, Weiss J, West H, Giaccone G, Evans T, Kelly RJ, Desai B, Krivoshik A, et al: A phase I, dose escalation study of oral ASP8273 in patients with non-small cell lung cancers with epidermal growth factor receptor mutations. Clin Cancer Res. 23:7467–7473. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Park K, Lee JS, Lee KH, Kim JH, Min YJ, Cho JY, Han JY, Kim BS, Kim JS, Lee DH, et al: Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI). J Clin Oncol. 33(Suppl 15): S80842015. View Article : Google Scholar | |
|
Sequist LV, Rolfe L and Allen AR: Rociletinib in EGFR-mutated non-small-cell lung cancer. New Engl J Med. 373:578–579. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Pan R, Zhang X, Si X, Wang M and Zhang L: Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib. Thorac Cancer. 11:594–602. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Tan DS, Leighl NB, Riely GJ, Yang JC, Sequist LV, Wolf J, Seto T, Felip E, Aix SP, Jonnaert M, et al: Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: A multicentre, open-label, phase 1 study. Lancet Resp Med. 8:561–572. 2020. View Article : Google Scholar | |
|
Kim DW, Lee DH, Han JY, Lee J, Cho BC, Kang JH, Lee KH, Cho EK, Kim JS, Min YJ, et al: Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. Lung Cancer. 135:66–72. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Shi Y, Zhang S, Hu X, Feng J, Ma Z, Zhou J, Yang N, Wu L, Liao W, Zhong D, et al: Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC With EGFR T790M mutation. J Thorac Oncol. 15:1015–1026. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yang JC, Camidge DR, Yang CT, Zhou J, Guo R, Chiu CH, Chang GC, Shiah HS, Chen Y, Wang CC, et al: Safety, efficacy, and pharmacokinetics of almonertinib (HS-10296) in pretreated patients with EGFR-mutated advanced NSCLC: A multicenter, open-label, phase 1 Trial. J Thorac Oncol. 15:1907–1918. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ahn MJ, Han JY, Lee KH, Kim SW, Kim DW, Lee YG, Cho EK, Kim JH, Lee GW, Lee JS, et al: Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. Lancet Oncol. 20:1681–1690. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kelly RJ, Shepherd FA, Krivoshik A, Jie F and Horn L: A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer. Ann Oncol. 30:1127–1133. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Mezquita L, Varga A and Planchard D: Safety of osimertinib in EGFR-mutated non-small cell lung cancer. Expert Opin Drug Saf. 17:1239–1248. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, et al: Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC. New Engl J Med. 382:41–50. 2020. View Article : Google Scholar | |
|
Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, et al: CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. Aug 28–2018.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI | |
|
Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, et al: Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): Interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 20:625–635. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Goldberg SB, Redman MW, Lilenbaum R, Politi K, Stinchcombe TE, Horn L, Chen EH, Mashru SH, Gettinger SN, Melnick MA, et al: Randomized trial of afatinib plus cetuximab versus afatinib alone for first-line treatment of -mutant non-small-cell lung cancer: Final results from SWOG S1403. J Clin Oncol. 38:4076–4085. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Oxnard GR, Yang JC, Yu H, Kim SW, Saka H, Horn L, Goto K, Ohe Y, Mann H, Thress KS, et al: TATTON: A multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol. 31:507–516. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Sequist LV, Piotrowska Z, Niederst MJ, Heist RS, Digumarthy S, Shaw AT and Engelman JA: Osimertinib responses after disease progression in patients who had been receiving rociletinib. JAMA Oncol. 2:541–543. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Nagasaka M, Zhu VW, Lim SM, Greco M, Wu F and Ou SI: Beyond osimertinib: The development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC. J Thorac Oncol. 16:740–763. 2021. View Article : Google Scholar | |
|
Ma Y, Zheng X, Zhao H, Fang W, Zhang Y, Ge J, Wang L, Wang W, Jiang J, Chuai S, et al: First-in-human phase I study of AC0010, a mutant-selective EGFR inhibitor in non-small cell lung cancer: Safety, efficacy, and potential mechanism of resistance. J Thorac Oncol. 13:968–977. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Zhang L, Hu P, Zheng X, Si X, Zhang X and Wang M: Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation. Lung Cancer. 122:1–6. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kim ES: Olmutinib: First global approval. Drugs. 76:1153–1157. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, Zakowski MF, Kris MG and Ladanyi M: EGFR exon 20 insertion mutations in lung adenocarcinomas: Prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 12:220–229. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, et al: Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 24:638–646. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Qin Y, Jian H, Tong X, Wu X, Wang F, Shao YW and Zhao X: Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors. Mol Oncol. 14:1695–1704. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
van Veggel B, Madeira R, Santos JFV, Hashemi SMS, Paats MS, Monkhorst K, Heideman DAM, Groves M, Radonic T, Smit EF, et al: Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. Lung Cancer. 141:9–13. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Wang S, Li B, Wang Z, Shang S, Shao Y, Sun X and Wang L: BIM deletion polymorphism confers resistance to osimertinib in EGFR T790M lung cancer: A case report and literature review. Target Oncol. 13:517–523. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao M, Zhang Y, Cai W, Li J, Zhou F, Cheng N, Ren R, Zhao C, Li X, Ren S, et al: The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer. Cancer. 120:2299–2307. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tanimoto A, Takeuchi S, Arai S, Fukuda K, Yamada T, Roca X, Ong ST and Yano S: Histone deacetylase 3 inhibition overcomes BIM deletion polymorphism-mediated osimertinib resistance in EGFR-mutant lung cancer. Clin Cancer Res. 23:3139–3149. 2017. View Article : Google Scholar | |
|
Isobe K, Hata Y, Tochigi N, Kaburaki K, Kobayashi H, Makino T, Otsuka H, Sato F, Ishida F, Kikuchi N, et al: Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation. J Thorac Oncol. 9:483–487. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu SY, Zhou JY, Li WF, Sun H, Zhang YC, Yan HH, Chen ZH, Chen CX, Ye JY, Yang JJ, et al: Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR-mutant advanced NSCLC than BIM deletion polymorphism. Clin Transl Med. 10:337–345. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Papadimitrakopoulou VA, Wu YL, Han JY, Ahn MJ, Ramalingam SS, John T, Okamoto I, Yang JCH, Bulusu KC, Laus G, et al: Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. Ann Oncol. 29(Suppl 8): VIII7412018. View Article : Google Scholar | |
|
Yang Z, Yang N, Ou Q, Xiang Y, Jiang T, Wu X, Bao H, Tong X, Wang X, Shao YW, et al: Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. Clin Cancer Res. 24:3097–3107. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, Hicks JK, Lovinger KL, Roarty E, Rinsurongkawong W, et al: Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in -mutant NSCLC. Clin Cancer Res. 24:6195–6203. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, et al: Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 4:1527–1534. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lin CC, Shih JY, Yu CJ, Ho CC, Liao WY, Lee JH, Tsai TH, Su KY, Hsieh MS, Chang YL, et al: Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: A genomic study. Lancet Resp Med. 6:107–116. 2018. View Article : Google Scholar | |
|
Ramalingam SS, Cheng Y, Zhou C, Ohe Y, Imamura F, Cho BC, Lin MC, Majem M, Shah R, Rukazenkov Y, et al: Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. Ann Oncol. 29(Suppl 8): viii7402018. View Article : Google Scholar | |
|
Ramalingam SS, Yang JC, Lee CK, Kurata T, Kim DW, John T, Nogami N, Ohe Y, Mann H, Rukazenkov Y, et al: Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol. 36:841–849. 2018. View Article : Google Scholar | |
|
Zhang YC, Chen ZH, Zhang XC, Xu CR, Yan HH, Xie Z, Chuai SK, Ye JY, Han-Zhang H, Zhang Z, et al: Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial. EBioMedicine. 43:180–187. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, et al: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 7:118152016. View Article : Google Scholar : PubMed/NCBI | |
|
Helman E, Nguyen M, Karlovich CA, Despain D, Choquette AK, Spira AI, Yu HA, Camidge DR, Harding TC, Lanman RB and Simmons AD: Cell-Free DNA next-generation sequencing prediction of response and resistance to third-generation EGFR inhibitor. Clin Lung Cancer. 19:530.e72018. View Article : Google Scholar | |
|
Ercan D, Choi HG, Yun CH, Capelletti M, Xie T, Eck MJ, Gray NS and Jänne PA: EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clin Cancer Res. 21:3913–3923. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Song HN, Jung KS, Yoo KH, Cho J, Lee JY, Lim SH, Kim HS, Sun JM, Lee SH, Ahn JS, et al: Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR inhibitor (HM61713) in non-small cell lung cancer. J Thorac Oncol. 11:e45–e47. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Park S, Ku BM, Jung HA, Sun JM, Ahn JS, Lee SH, Park K and Ahn MJ: EGFR C797S as a resistance mechanism of lazertinib in non-small cell lung cancer with EGFR T790M mutation. Cancer Res Treat. 52:1288–1290. 2020.PubMed/NCBI | |
|
Oztan A, Fischer S, Schrock AB, Erlich RL, Lovly CM, Stephens PJ, Ross JS, Miller V, Ali SM, Ou SI and Raez LE: Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib. Lung Cancer. 111:84–87. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Fassunke J, Muller F, Keul M, Michels S, Dammert MA, Schmitt A, Plenker D, Lategahn J, Heydt C, Bragelmann J, et al: Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nat Commun. 9:46552018. View Article : Google Scholar | |
|
Bersanelli M, Minari R, Bordi P, Gnetti L, Bozzetti C, Squadrilli A, Lagrasta CA, Bottarelli L, Osipova G, Capelletto E, et al: L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-Mutated NSCLC. J Thorac Oncol 11: e121-e123,. 2016. | |
|
Zhao S, Li X, Zhao C, Jiang T, Jia Y, Shi J, He Y, Li J, Zhou F, Gao G, et al: Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M. Lung Cancer. 128:33–39. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, Fulton L, Hata AN, Lockerman EL, Kalsy A, et al: Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov. 5:713–722. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Knebel FH, Bettoni F, Shimada AK, Cruz M, Alessi JV, Negrão MV, Reis LFL, Katz A and Camargo AA: Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC. Lung Cancer. 108:238–241. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Q, Yang S, Wang K and Sun SY: MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol. 12:632019. View Article : Google Scholar : PubMed/NCBI | |
|
Drilon A, Cappuzzo F, Ou SI and Camidge DR: Targeting MET in lung cancer: Will expectations finally Be MET? J Thorac Oncol. 12:15–26. 2017. View Article : Google Scholar : | |
|
Hsu CC, Liao BC, Liao WY, Markovets A, Stetson D, Thress K and Yang JC: Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-positive non-small cell lung cancer. J Thorac Oncol. 15:50–61. 2020. View Article : Google Scholar | |
|
Desai A and Adjei AA: FGFR signaling as a target for lung cancer therapy. J Thorac Oncol. 11:9–20. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kim TM, Song A, Kim DW, Kim S, Ahn YO, Keam B, Jeon YK, Lee SH, Chung DH and Heo DS: Mechanisms of acquired resistance to AZD9291: A mutation-selective, irreversible EGFR inhibitor. J Thorac Oncol. 10:1736–1744. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ou SI, Horn L, Cruz M, Vafai D, Lovly CM, Spradlin A, Williamson MJ, Dagogo-Jack I, Johnson A, Miller VA, et al: Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. Lung Cancer. 111:61–64. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hayakawa D, Takahashi F, Mitsuishi Y, Tajima K, Hidayat M, Winardi W, Ihara H, Kanamori K, Matsumoto N, Asao T, et al: Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation. Thorac Cancer. 11:140–149. 2020. View Article : Google Scholar | |
|
Manabe T, Yasuda H, Terai H, Kagiwada H, Hamamoto J, Ebisudani T, Kobayashi K, Masuzawa K, Ikemura S, Kawada I, et al: IGF2 Autocrine-Mediated IGF1R activation is a clinically relevant mechanism of osimertinib resistance in lung cancer. Mol Cancer Res. 18:549–559. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, et al: AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nat Commun. 10:2592019. View Article : Google Scholar : PubMed/NCBI | |
|
Namba K, Shien K, Takahashi Y, Torigoe H, Sato H, Yoshioka T, Takeda T, Kurihara E, Ogoshi Y, Yamamoto H, et al: Activation of AXL as a preclinical acquired resistance mechanism against osimertinib treatment in EGFR-mutant non-small cell lung cancer cells. Mol Cancer Res. 17:499–507. 2019. View Article : Google Scholar | |
|
Nakatani K, Yamaoka T, Ohba M, Fujita KI, Arata S, Kusumoto S, Taki-Takemoto I, Kamei D, Iwai S, Tsurutani J and Ohmori T: KRAS and EGFR amplifications mediate resistance to rociletinib and osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in. Mol Cancer Ther. 18:112–126. 2019. View Article : Google Scholar | |
|
Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, et al: EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: Clinical outcomes. J Clin Oncol. 37:278–285. 2019. View Article : Google Scholar | |
|
Schoenfeld AJ, Chan JM, Kubota D, Sato H, Rizvi H, Daneshbod Y, Chang JC, Paik PK, Offin M, Arcila ME, et al: Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer. Clin Cancer Res. 26:2654–2663. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Dongre A and Weinberg RA: New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 20:69–84. 2019. View Article : Google Scholar | |
|
Nukaga S, Yasuda H, Tsuchihara K, Hamamoto J, Masuzawa K, Kawada I, Naoki K, Matsumoto S, Mimaki S, Ikemura S, et al: Amplification of EGFR wild-type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors. Cancer Res. 77:2078–2089. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Weng CH, Chen LY, Lin YC, Shih JY, Lin YC, Tseng RY, Chiu AC, Yeh YH, Liu C, Lin YT, et al: Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI. Oncogene. 38:455–468. 2019. View Article : Google Scholar | |
|
Schrock AB, Zhu VW, Hsieh WS, Madison R, Creelan B, Silberberg J, Costin D, Bharne A, Bonta I, Bosemani T, et al: Receptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 13:1312–1323. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Batra U, Sharma M, Amrith BP, Mehta A and Jain P: EML4-ALK fusion as a resistance mechanism to osimertinib and its successful management with osimertinib and alectinib: Case report and review of the literature. Clin Lung Cancer. 21:e597–e600. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jia Y, Yun CH, Park E, Ercan D, Manuia M, Juarez J, Xu C, Rhee K, Chen T, Zhang H, et al: Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 534:129–132. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Uchibori K, Inase N, Araki M, Kamada M, Sato S, Okuno Y, Fujita N and Katayama R: Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat Commun. 8:147682017. View Article : Google Scholar : PubMed/NCBI | |
|
Schalm SS, Dineen T, Lim SM, Park CW, Hsieh J, Woessner R, Zhang Z, Wilson K, Eno M, Wilson D, et al: 1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC. Ann Oncol. 31(Suppl 6): S1386–S1406. 2020. | |
|
Liu X, Zhang X, Yang L, Tian X, Dong T, Ding CZ, Hu L, Wu L, Zhao L, Mao J, et al: Abstract 1320: Preclinical evaluation of TQB3804, a potent EGFR C797S inhibitor. 79(Suppl 13): S13202019. | |
|
Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, Huber RM, West HL, Groen HJ, Hochmair MJ, et al: Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: A randomized, multicenter phase II trial. J Clin Oncol. 35:2490–2498. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Yang N, Zhang Y, Li L, Han R, Zhu M, Feng M, Chen H, Lizaso A, Qin T, et al: Effective treatment of lung adenocarcinoma harboring EGFR-activating mutation, T790M, and cis-C797S triple mutations by brigatinib and cetuximab combination therapy. J Thorac Oncol. 15:1369–1375. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao J, Zou M, Lv J, Han Y and Wang G and Wang G: Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and -C797S by osimertinib, bevacizumab, and brigatinib combination therapy: A case report. Onco Targets Ther. 11:5545–5550. 2018. View Article : Google Scholar : | |
|
Arulananda S, Do H, Musafer A, Mitchell P, Dobrovic A and John T: Combination osimertinib and gefitinib in C797S and T790M EGFR-mutated non-small cell lung cancer. J Thorac Oncol. 12:1728–1732. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Giroux-Leprieur E, Dumenil C and Chinet T: Combination of crizotinib and osimertinib or erlotinib might overcome MET-mediated resistance to EGFR Tyrosine kinase inhibitor in EGFR-mutated adenocarcinoma. J Thorac Oncol. 13:e232–e234. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, Yang JC, Lee JS, Su WC, Kowalski D, et al: Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: Interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 21:373–386. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Odogwu L, Mathieu L, Blumenthal G, Larkins E, Goldberg KB, Griffin N, Bijwaard K, Lee EY, Philip R, Jiang X, et al: FDA approval summary: Dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations. Oncologist. 23:740–745. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Oh DK, Ji WJ, Kim WS, Choi CM, Yoon SK, Rho JK and Lee JC: Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice. PLoS One. 14:e02102252019. View Article : Google Scholar : PubMed/NCBI | |
|
Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, Marcoux N, Banwait MK, Digumarthy SR, Su W, et al: Landscape of acquired resistance to osimertinib in EGFR-Mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired fusion. Cancer Discov. 8:1529–1539. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Han R, Hao S, Lu C, Zhang C, Lin C, Li L, Wang Y, Hu C and He Y: Aspirin sensitizes osimertinib-resistant NSCLC cells in vitro and in vivo via Bim-dependent apoptosis induction. Mol Oncol. 14:1152–1169. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, Sequist LV and Engelman JA: The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res. 21:3924–3933. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Yang JJ, Huang J, Ye JY, Zhang XC, Tu HY, Han-Zhang H and Wu YL: Lung Adenocarcinoma Harboring EGFR T790M and in trans C797S responds to combination therapy of first- and third-generation EGFR TKIs and shifts allelic configuration at resistance. J Thorac Oncol. 12:1723–1727. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Rotow JK, Costa DB, Paweletz CP, Awad MM, Marcoux P, Rangachari D, Barbie DA, Sands J, Cheng ML, Johnson BE, et al: Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC). J Clin Oncol. 38:95072020. View Article : Google Scholar | |
|
Chic N, Mayo-de-Las-Casas C and Reguart N: Successful treatment with gefitinib in advanced non-small cell lung cancer after acquired resistance to osimertinib. J Thorac Oncol. 12:e78–e80. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Rangachari D, To C, Shpilsky JE, VanderLaan PA, Kobayashi SS, Mushajiang M, Lau CJ, Paweletz CP, Oxnard GR, Jänne PA and Costa DB: EGFR-mutated lung cancers resistant to osimertinib through EGFR C797S respond to first-generation reversible EGFR inhibitors but eventually acquire EGFR T790M/C797S in preclinical models and clinical samples. J Thorac Oncol. 14:1995–2002. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yang X, Huang C, Chen R and Zhao J: Resolving resistance to osimertinib therapy with afatinib in an NSCLC patient with EGFR L718Q mutation. Clin Lung Cancer. 21:e258–e260. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Romaniello D, Mazzeo L, Mancini M, Marrocco I, Noronha A, Kreitman M, Srivastava S, Ghosh S, Lindzen M, Salame TM, et al: A combination of approved antibodies overcomes resistance of lung cancer to osimertinib by blocking bypass pathways. Clin Cancer Res. 24:5610–5621. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yu HA, Baik CS, Gold K, Hayashi H, Johnson M, Koczywas M, Murakami H, Nishio M, Steuer C, Su WC, et al: LBA62 Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC. Ann Oncol. 31:S1189–S1190. 2020. View Article : Google Scholar | |
|
Cho BC, Lee KH, Cho EK, Kim DW, Lee JS, Han JY, Kim SW, Spira A, Haura EB, Sabari JK, et al: 1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC. Ann Oncol. 31(Suppl 4): S8132020. View Article : Google Scholar | |
|
Okura N, Nishioka N, Yamada T, Taniguchi H, Tanimura K, Katayama Y, Yoshimura A, Watanabe S, Kikuchi T, Shiotsu S, et al: ONO-7475, a Novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in -mutated non-small cell lung cancer. Clin Cancer Res. 26:2244–2256. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kim D, Bach DH, Fan YH, Luu TT, Hong JY, Park HJ and Lee SK: AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells. Cell Death Dis. 10:3612019. View Article : Google Scholar : PubMed/NCBI | |
|
Yang YM, Jang Y, Lee SH, Kang B and Lim SM: AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation. Lung Cancer. 46:70–77. 2020. View Article : Google Scholar | |
|
Shi P, Oh YT, Deng L, Zhang G, Qian G, Zhang S, Ren H, Wu G, Legendre B Jr, Anderson E, et al: Overcoming acquired resistance to AZD9291, A third-generation EGFR inhibitor, through modulation of MEK/ERK-dependent Bim and Mcl-1 Degradation. Clin Cancer Res. 23:6567–6579. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gu J, Yao W, Shi P, Zhang G, Owonikoko TK, Ramalingam SS and Sun SY: MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers. Cancer. 126:3788–3799. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xie Z, Gu Y, Xie X, Lin X, Ouyang M, Qin Y, Zhang J, Lizaso A, Chen S and Zhou C: Lung adenocarcinoma harboring concomitant EGFR mutations and BRAF V600E responds to a combination of osimertinib and vemurafenib to overcome osimertinib resistance. Clin Lung Cancer. 22:e390–e394. 2021. View Article : Google Scholar | |
|
Raoof S, Mulford IJ, Frisco-Cabanos H, Nangia V, Timonina D, Labrot E, Hafeez N, Bilton SJ, Drier Y, Ji F, et al: Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene. 38:6399–6413. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yochum ZA, Cades J, Wang H, Chatterjee S, Simons BW, O'Brien JP, Khetarpal SK, Lemtiri-Chlieh G, Myers KV, Huang EH, et al: Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene. 38:656–670. 2019. View Article : Google Scholar | |
|
Yang JC, Schuler M, Popat S, Miura S, Heeke S, Park K, Märten A and Kim ES: Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: A database of 693 cases. J Thorac Oncol. 15:803–815. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Fang W, Huang Y, Gan J, Shao YW and Zhang L: Durable response of low-dose afatinib plus cetuximab in an adenocarcinoma patient with a novel EGFR exon 20 insertion mutation. J Thorac Oncol. 14:e220–e221. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hasegawa H, Yasuda H, Hamamoto J, Masuzawa K, Tani T, Nukaga S, Hirano T, Kobayashi K, Manabe T, Terai H, et al: Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations. Lung Cancer. 127:146–152. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
van Veggel B, de Langen AJ, Hashemi SMS, Monkhorst K, Heideman DAM, Thunnissen E and Smit EF: Afatinib and cetuximab in four patients with EGFR exon 20 insertion-positive advanced NSCLC. J Thorac Oncol. 13:1222–1226. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yun J, Lee SH, Kim SY, Jeong SY, Kim JH, Pyo KH, Park CW, Heo SG, Yun MR, Lim S, et al: Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of exon 20 insertion-driven NSCLC. Cancer Discov. 10:1194–1209. 2020.PubMed/NCBI | |
|
Riely GJ, Neal JW, Camidge DR, Spira A, Piotrowska Z, Horn L, Costa DB, Tsao A, Patel J, Gadgeel S, et al: 1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins). Ann Oncol. 31:S815–S816. 2020. View Article : Google Scholar | |
|
Nakahara Y, Kato T, Isomura R, Seki N, Furuya N, Naoki K, Yamanaka T and Okamoto H: A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer: TORG1833. J Clin Oncol. 37:TPS91202019. View Article : Google Scholar | |
|
Yu HA, Schoenfeld AJ, Makhnin A, Kim R, Rizvi H, Tsui D, Falcon C, Houck-Loomis B, Meng F, Yang JL, et al: Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: A Phase 1/2 single-group open-label trial. JAMA Oncol. 6:1048–1054. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kobayashi N, Hashimoto H, Kamimaki C, Nagasawa R, Tanaka K, Kubo S, Katakura S, Chen H, Hirama N, Ushio R, et al: Afatinib + bevacizumab combination therapy in EGFR-mutant NSCLC patients with osimertinib resistance: Protocol of an open-label, phase II, multicenter, single-arm trial. Thorac Cancer. 11:2125–2129. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lisberg A, Cummings A, Goldman JW, Bornazyan K, Reese N, Wang T, Coluzzi P, Ledezma B, Mendenhall M, Hunt J, et al: A phase II study of pembrolizumab in EGFR-Mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC. J Thorac Oncol. 13:1138–1145. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ahn MJ, Yang J, Yu H, Saka H, Ramalingam S, Goto K, Kim SW, Yang L, Walding A and Oxnard GR: 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial. J Thorac Oncol. 11:S1152016. View Article : Google Scholar | |
|
Zhou J, Zhou F, Xie H, Wu Y, Zhao J and Su C: An advanced non-small cell lung cancer patient with epidermal growth factor receptor sensitizing mutation responded to toripalimab in combination with chemotherapy after resistance to osimertinib: A case report. Transl Lung Cancer Res. 9:354–359. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang YC, Zhou Q and Wu YL: Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: Current status and future perspectives. Cancer Lett. 459:240–247. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wu YL, Planchard D, Lu S, Sun H, Yamamoto N, Kim DW, Tan DSW, Yang JC, Azrif M, Mitsudomi T, et al: Pan-Asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol. 30:171–210. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Non-Small Cell Lung Cancer Version 4. NCCN Clinical Practice Guidelines in Oncology. 2021, https://www.nccn.org. Accessed at 25 Jun 2021. | |
|
Jang J, To C, De Clercq DJH, Park E, Ponthier CM, Shin BH, Mushajiang M, Nowak RP, Fischer ES, Eck MJ, et al: Mutant-selective allosteric EGFR degraders are effective against a broad range of drug-resistant mutations. Angew Chem Int Ed Engl. 59:14481–14489. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
To C, Jang J, Chen T, Park E, Mushajiang M, De Clercq DJH, Xu M, Wang S, Cameron MD, Heppner DE, et al: Single and dual targeting of mutant EGFR with an allosteric inhibitor. Cancer Discov. 9:926–943. 2019. View Article : Google Scholar : PubMed/NCBI |
